Understanding the FDA’s Guidance on Diversity in Clinical Research

In recent years, the U.S. Food and Drug Administration (FDA) has taken bold steps to improve diversity in clinical trials. The lack of adequate representation of racial, ethnic, and other demographic groups has long hindered the generalizability and ethical integrity of research. To address this, the FDA released a draft guidance titled “Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials” and has introduced mandatory requirements under FDORA Section 3602.

This article provides a comprehensive overview of the FDA’s current expectations for diversity planning and reporting in clinical research, and how sponsors can remain compliant while promoting inclusive and equitable trial practices.

Why Diversity Matters in Clinical Research

Clinical trial participants should reflect the populations most likely to use the treatment. Without adequate representation, sponsors risk:

• Failing to detect differential safety or efficacy responses
• Excluding real-world populations due to restrictive eligibility
• Regulatory scrutiny or delay in approvals
• Lack of trust from historically marginalized communities

According to the USFDA, diverse participation is crucial for robust drug development and ethical standards of research.

Overview of the FDA’s 2022 Draft Guidance

The FDA’s draft guidance encourages sponsors to submit a “Race and Ethnicity Diversity Plan” early in clinical development. This plan should outline:

1. Enrollment Goals: Target numbers for racial and ethnic representation
2. Demographic Justification: Epidemiological data to support enrollment targets
3. Recruitment Strategies: Site selection, community engagement, and inclusive materials
4. Retention Plans: Addressing logistical and cultural barriers to continued participation

This plan aligns with efforts toward greater transparency and accountability across the drug development continuum.

FDORA Section 3602: Mandating Diversity Plans

In December 2022, the Food and Drug Omnibus Reform Act (FDORA) was enacted, legally requiring diversity action plans for all Phase 3 or pivotal studies. Section 3602 stipulates that:

• Sponsors must submit a diversity action plan with demographic targets and strategy
• Any deviation must be justified and may delay FDA review
• Plans are subject to public reporting and inspection

Failure to comply can affect regulatory timelines and reputational standing.

Building a Compliant Diversity Plan

To align with FDA expectations, a strong diversity plan should include:

• Target enrollment proportions based on U.S. Census and disease prevalence data
• Engagement with advocacy and community-based organizations
• Translated and culturally appropriate consent materials
• Geographically diverse site selection
• Internal DEI training for research staff per Pharmaceutical SOP guidelines

Tracking tools should enable real-time oversight of diversity performance across sites.

Best Practices for Achieving Enrollment Goals

Sponsors can enhance success by implementing:

1. Inclusive Protocol Design: Avoid exclusion criteria that disproportionately affect minorities
2. Community Trust Building: Partner with local leaders, churches, and non-profits
3. Bilingual/Bicultural Staff: Improves participant communication and comfort
4. Logistical Support: Transportation, childcare, and flexible visit windows
5. Digital Engagement: Use social media and mobile apps targeted at underrepresented populations

Case Example: Alzheimer’s Trial Meeting FDA Diversity Goals

A global Phase 3 Alzheimer’s trial integrated a Race and Ethnicity Diversity Plan from the start. The sponsor:

• Used epidemiological models to set Hispanic and African American enrollment targets
• Incentivized sites to meet diversity metrics
• Trained staff using SOP validation in pharma protocols for patient engagement
• Held community events in both English and Spanish

Outcome: 24% of participants were from underrepresented racial or ethnic groups, surpassing FDA-recommended benchmarks.

Monitoring and Reporting Metrics

Key metrics that sponsors should monitor include:

• Enrollment by race and ethnicity over time
• Site-level performance on inclusion goals
• Participant dropout stratified by demographic group
• Post-study follow-up rates by subgroup

These metrics can be aligned with ongoing Stability Studies or internal audits for quality assurance.

Preparing for FDA Inspections and Submissions

To avoid inspection findings or review delays:

• Document all diversity-related decisions and justifications
• Maintain complete records of community outreach and engagement activities
• Use standardized formats for reporting diversity data
• Incorporate diversity performance into investigator meetings and site monitoring

Conclusion: A New Era of Inclusive Research

The FDA’s guidance and legal mandates mark a paradigm shift in how clinical research is conducted. Sponsors must now approach diversity with the same rigor as efficacy and safety. By embracing these changes proactively—through strategic planning, community partnerships, and data-driven recruitment—clinical trials can become more inclusive, equitable, and scientifically valid.